Neurobiology of Alcohol and Nicotine Co-Addiction
Status: | Recruiting |
---|---|
Conditions: | Smoking Cessation, Tobacco Consumers |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - 55 |
Updated: | 4/17/2018 |
Start Date: | February 8, 2018 |
End Date: | January 1, 2020 |
Contact: | Laura Research Assistant, BS |
Email: | dennisl@ohsu.edu |
Phone: | 503-721-7964 |
This proposal addresses the critical absence of information about the neurobiology of
recovery from Alcohol Use Disorder (AUD) in alcohol and nicotine users. AUD and nicotine use
disorder (NUD) are the most commonly abused (non-prescription) substances in the U.S.
Co-addiction is particularly high in military veterans. Although nationwide estimates peg the
rate of AUD/NUD co-addiction at 80%, the Substance Abuse Treatment Program (SATP) at the
Veterans Affairs Portland Health Care System (VAPORHCS) finds that 90% of veterans treated
for AUD also meet criteria for NUD. The investigators hypothesize that a support vector
machine learning algorithm will be able to use the measures to classify subjects as AUD, NUD
both or neither and that the algorithm will predict outcome (sobriety or relapse) at three
months.
recovery from Alcohol Use Disorder (AUD) in alcohol and nicotine users. AUD and nicotine use
disorder (NUD) are the most commonly abused (non-prescription) substances in the U.S.
Co-addiction is particularly high in military veterans. Although nationwide estimates peg the
rate of AUD/NUD co-addiction at 80%, the Substance Abuse Treatment Program (SATP) at the
Veterans Affairs Portland Health Care System (VAPORHCS) finds that 90% of veterans treated
for AUD also meet criteria for NUD. The investigators hypothesize that a support vector
machine learning algorithm will be able to use the measures to classify subjects as AUD, NUD
both or neither and that the algorithm will predict outcome (sobriety or relapse) at three
months.
Inclusion Criteria:
Exclusion Criteria:
We found this trial at
1
site
Portland, Oregon 97239
Principal Investigator: William F Hoffman, MD, PhD
Phone: 503-721-7964
Click here to add this to my saved trials